These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19322980)

  • 1. Exenatide and acute pancreatitis.
    Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
    J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 3. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
    Cvetković RS; Plosker GL
    Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cohort study of acute pancreatitis in relation to exenatide use.
    Dore DD; Bloomgren GL; Wenten M; Hoffman C; Clifford CR; Quinn SG; Braun DK; Noel RA; Seeger JD
    Diabetes Obes Metab; 2011 Jun; 13(6):559-66. PubMed ID: 21320263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
    Al-Jebawi AF
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e88-90. PubMed ID: 21030101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Exenatide (Byetta)].
    Duh D; Vandevijver A
    J Pharm Belg; 2008 Mar; 63(1):29-30. PubMed ID: 18479081
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of type 2 diabetes mellitus and the incretin system.
    Whitehill D
    S D Med; 2007 May; 60(5):197, 199. PubMed ID: 17694940
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia.
    Cohen V; Teperikidis E; Jellinek SP; Rose J
    Clin Toxicol (Phila); 2008 Apr; 46(4):346-7. PubMed ID: 17852164
    [No Abstract]   [Full Text] [Related]  

  • 13. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide: pancreatitis. Watch out for nausea and vomiting.
    Prescrire Int; 2008 Jun; 17(95):112. PubMed ID: 18630353
    [No Abstract]   [Full Text] [Related]  

  • 15. [Improved blood sugar control plus weight loss].
    Göke B
    MMW Fortschr Med; 2006 Aug; 148(33-34):51. PubMed ID: 16981389
    [No Abstract]   [Full Text] [Related]  

  • 16. Insulin initiation in Type 2 diabetes.
    Page S
    Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
    [No Abstract]   [Full Text] [Related]  

  • 17. Exenatide: excessive weight loss.
    Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
    [No Abstract]   [Full Text] [Related]  

  • 18. Exenatide: pancreatitis. Gastrointestinal symptoms.
    Prescrire Int; 2009 Apr; 18(100):69. PubMed ID: 19588557
    [No Abstract]   [Full Text] [Related]  

  • 19. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.